GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (STU:ET80) » Definitions » Price-to-Funds-From-Operations

AEterna Zentaris (STU:ET80) Price-to-Funds-From-Operations : (As of Jun. 07, 2024)


View and export this data going back to 1995. Start your Free Trial

What is AEterna Zentaris Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


AEterna Zentaris (STU:ET80) Business Description

Traded in Other Exchanges
Address
222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.